JAK1 and hepatocellular carcinoma: JAK1 mutations have been identified in hepatocellular carcinoma (HCC) patient tumors; patient-derived xenografts with JAK1 S703I mutations had elevated levels of phosphorylated STAT3 and STAT5[40,41].